Literature DB >> 19136143

Understanding the epidemiology and progression of systemic lupus erythematosus.

Guillermo J Pons-Estel1, Graciela S Alarcón, Lacie Scofield, Leslie Reinlib, Glinda S Cooper.   

Abstract

OBJECTIVES: This review examines the burden and patterns of disease in systemic lupus erythematosus (SLE) and the influence and interactions of gender, ethnicity, age, and psychosocial attributes with respect to disease progression, focusing on issues relevant to clinical practice and research.
METHODS: PubMed literature search complemented by review of bibliographies listed in identified articles.
RESULTS: An increased risk among reproductive age women is clearly seen in African Americans in the United States. However, in other populations, a different pattern is generally seen, with the highest age-specific incidence rates occurring in women after age 40 years. The disease is 2 to 4 times more frequent, and more severe, among nonwhite populations around the world and tends to be more severe in men and in pediatric and late-onset lupus. SLE patients now experience a higher than 90% survival rate at 5 years. The less favorable survival experience of ethnic minorities is possibly related to socioeconomic status rather than to ethnicity per se, and adequate social support has been shown to be a protective factor, in general, in SLE patients. Discordance between physician and patient ratings of disease activity may affect quality of care.
CONCLUSIONS: Our understanding of ways to improve outcomes in SLE patients could benefit from patient-oriented research focusing on many dimensions of disease burden. Promising research initiatives include the inclusion of community-based patients in longitudinal studies, use of self-assessment tools for rating disease damage and activity, and a focus on self-perceived disease activity and treatment compliance. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19136143      PMCID: PMC2813992          DOI: 10.1016/j.semarthrit.2008.10.007

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  127 in total

1.  Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus.

Authors:  M MERRELL; L E SHULMAN
Journal:  J Chronic Dis       Date:  1955-01

2.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.

Authors:  Sergio M A Toloza; América G Uribe; Gerald McGwin; Graciela S Alarcón; Barri J Fessler; Holly M Bastian; Luis M Vilá; Ruihua Wu; Yehuda Shoenfeld; Jeffrey M Roseman; John D Reveille
Journal:  Arthritis Rheum       Date:  2004-12

3.  Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support.

Authors:  Rebecca L Jump; Michael E Robinson; Ashley E Armstrong; Elena V Barnes; Kristin M Kilbourn; Hanno B Richards
Journal:  J Rheumatol       Date:  2005-09       Impact factor: 4.666

4.  Lack of recording of systemic lupus erythematosus in the death certificates of lupus patients.

Authors:  J Calvo-Alén; G S Alarcón; R Campbell; M Fernández; J D Reveille; G S Cooper
Journal:  Rheumatology (Oxford)       Date:  2005-06-14       Impact factor: 7.580

5.  Major life stress, coping styles, and social support in relation to psychological distress in patients with systemic lupus erythematosus.

Authors:  E Kozora; M C Ellison; J A Waxmonsky; F S Wamboldt; T L Patterson
Journal:  Lupus       Date:  2005       Impact factor: 2.911

6.  Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective population-based study in Taiwan.

Authors:  J L Huang; T C Yao; L C See
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

Review 7.  Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature.

Authors:  Jacques Boddaert; Du Le Thi Huong; Zahir Amoura; Bertrand Wechsler; Pierre Godeau; Jean-Charles Piette
Journal:  Medicine (Baltimore)       Date:  2004-11       Impact factor: 1.889

8.  Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. SLE Disease Activity Index.

Authors:  F Formiga; I Moga; M Pac; F Mitjavila; A Rivera; R Pujol
Journal:  Lupus       Date:  1999       Impact factor: 2.911

9.  Epidemiology treatment and outcome of childhood systemic lupus erythematosus in Egypt.

Authors:  Ashraf Bakr
Journal:  Pediatr Nephrol       Date:  2005-06-07       Impact factor: 3.714

10.  Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age.

Authors:  S Rinaldi; A Doria; F Salaffi; M Ermani; L Iaccarino; A Ghirardello; S Zampieri; P Sarzi-Puttini; P F Gambari; G Perini
Journal:  Rheumatology (Oxford)       Date:  2004-09-07       Impact factor: 7.580

View more
  239 in total

1.  Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States.

Authors:  Sudumpai Jarukitsopa; Deana D Hoganson; Cynthia S Crowson; Olayemi Sokumbi; Mark D Davis; Clement J Michet; Eric L Matteson; Hilal Maradit Kremers; Vaidehi R Chowdhary
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

2.  Association between stillbirth and risk factors known at pregnancy confirmation.

Authors: 
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

3.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

4.  Commercial rodent diets differentially regulate autoimmune glomerulonephritis, epigenetics and microbiota in MRL/lpr mice.

Authors:  Michael R Edwards; Rujuan Dai; Bettina Heid; Thomas E Cecere; Deena Khan; Qinghui Mu; Catharine Cowan; Xin M Luo; S Ansar Ahmed
Journal:  Int Immunol       Date:  2017-06-01       Impact factor: 4.823

5.  Prevalence and incidence of systemic lupus erythematosus in South Korea.

Authors:  Jee-Seon Shim; Yoon-Kyoung Sung; Young Bin Joo; Hye-Soon Lee; Sang-Cheol Bae
Journal:  Rheumatol Int       Date:  2013-12-10       Impact factor: 2.631

6.  Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.

Authors:  Zhi-Wei Lai; Ryan Kelly; Thomas Winans; Ivan Marchena; Ashwini Shadakshari; Julie Yu; Maha Dawood; Ricardo Garcia; Hajra Tily; Lisa Francis; Stephen V Faraone; Paul E Phillips; Andras Perl
Journal:  Lancet       Date:  2018-03-15       Impact factor: 79.321

7.  C-reactive protein +1444CT (rs1130864) genetic polymorphism is associated with the susceptibility to systemic lupus erythematosus and C-reactive protein levels.

Authors:  Francieli Delongui; Marcell Allyson Batisti Lozovoy; Tatiana Mayiumi Veiga Iriyoda; Neide Tomimura Costa; Nicole Perugini Stadtlober; Daniela Frizon Alfieri; Tamires Flauzino; Isaias Dichi; Andréa Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Clin Rheumatol       Date:  2017-06-01       Impact factor: 2.980

Review 8.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

9.  Levels of serum procalcitonin and C-reactive protein for evaluating pulmonary bacterial infection in patients with lupus erythematosus.

Authors:  Jing Gao; Lei Zhang; Xin Zhang; Shi-Long Zhao; Sheng-Yun Liu; Li-Hua Xing
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

10.  Contemporary treatment of systemic lupus erythematosus: an update for clinicians.

Authors:  Maame B Amissah-Arthur; Caroline Gordon
Journal:  Ther Adv Chronic Dis       Date:  2010-07       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.